Nectar Lifesciences Limited
Incorporated in 1995, Nectar LifesciencesLtd manufactures APIs and Formulationsand is also in the Menthol business
What Nectar files
- Others78
- Updates20
- Important20
- Board Meeting12
- Dividend/Bonus7
- Results4
Nectar Lifesciences' Chairman & MD, Sanjiv Goyal, gifted 8,000,000 equity shares to Raman Goyal, a promoter group member. This off-market transfer shifts Sanjiv Goyal's stake from 24.90% to 21.33% and Raman Goyal's from 0.55% to 4.12%.
Nectar Lifesciences' promoters' 9.94 crore equity shares (44.35% stake) have been released from pledge. This follows the company's loan repayment, a positive development removing a significant overhang for investors.
Nectar Lifesciences has fully settled its secured debt with lenders. This results in the satisfaction of a ₹1,338.35 Cr charge on all company assets, significantly enhancing financial flexibility and balance sheet strength.
Nectar Lifesciences' Unit VI has secured Good Manufacturing Practices (GMP) certification from Ukraine's SMDC, enhancing its quality recognition for products. This certification is valid until April 2026. However, investors should note that the company's shareholders have already approved the slump sale of this Unit VI. While the unit achieved a...
Nectar Lifesciences shareholders approved key proposals at its Extraordinary General Meeting. They approved the appointment of Dr. Surulichamy Senthilkumar as a Director and as a Whole-time Director (R&D) for three years. Critically, shareholders also greenlit the transfer of the company's business to Ceph Lifesciences Private Limited on a 'slump sale'...